{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'for screening inclusion (INF or GA), they may be considered for this trial if they meet', 'all inclusion and exclusion criteria otherwise,', '-', 'Patient is the Investigator or any SubInvestigator, research assistant, pharmacist, study', 'coordinator, other staff or relative thereof directly involved in the conduct of the', 'protocol,', '-', 'Uncooperative patient or any condition that could make the patient potentially', 'noncompliant to the study procedures in the opinion of the Investigator.', 'E 03. Mental condition rendering the patient or parent/guardian unable to understand the nature,', 'scope, and possible consequences of the study.', 'E 04. Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major', 'systemic disease making implementation of the protocol or interpretation of the study', 'results difficult or that would put the patient at risk by participating in the study in the', 'opinion of the Investigator.', 'E 05. History of drug or alcohol abuse.', 'E 06. History of known HIV positivity.', '7.2.2 Exclusion criteria related to alemtuzumab and/or mandatory background therapies', 'E 07. Pregnant or breast-feeding female patients or those who plan to become pregnant during', 'the study.', 'E 08. Unwilling to agree to use a highly effective contraceptive method as defined (Appendix A)', 'when receiving a course of alemtuzumab treatment and for 4 months following that course', 'of treatment (fertile patients only).', 'E', '09. Female patients who have commenced menstruating (ie, are of childbearing potential) and', 'are unwilling or unable to be tested for pregnancy.', 'E 10. Previous treatment with alemtuzumab.', 'E 11. Treatment with natalizumab, daclizumab, fingolimod, methotrexate, azathioprine,', 'cyclosporine, or mycophenolate mofetil in the last 6 months prior to screening, or as', 'determined by the treating physician to have residual immune suppression from these or', 'other MS treatments.', 'E', '12. Treatment with teriflunomide in the last 12 months except if the patient underwent the', 'accelerated elimination procedure as per local teriflunomide label.', 'E 13. Previous treatment with mitoxantrone, cyclophosphamide, cladribine, rituximab,', 'ocrelizumab, leflunomide, or any cytotoxic therapy.', 'E 14. Previous treatment with any investigational medication (drug that has not been approved at', 'any dose or for any indication). Use of an investigational medication that was subsequently', 'licensed and nonstandard use of a licensed medication (eg, using a dose other than the dose', 'Property of the Sanofi Group - strictly confidential', 'Page 42', 'VV-CLIN-02544065.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'that is stated in the licensed product labeling or using a licensed therapy for an alternative', 'indication) is not exclusionary. Prior treatment with herbal medications or nutritional', 'supplements is also permitted.', 'E 15. Intolerance of pulsed corticosteroids, especially a history of steroid psychosis.', '7.2.3 Exclusion criteria related to the current knowledge of alemtuzumab and study', 'methodology', 'If a patient was deemed a screen failure, he or she may be re-screened for this study up to 2 times.', 'If a patient who previously failed screening for any reason is re-screened, the patient must sign a', 'new informed consent form and be assigned a new patient number by IWRS/IVRS (the next', 'sequential patient number at the site). All screening assessments need to be repeated to confirm', 'eligibility for the study. Rescreening assessments may be discussed with the Sponsor on a', 'case-by-case basis.', 'Medical History', 'E 16. History of malignancy.', 'E', '17. Prior documented history of thrombocytopenia, or platelet count at screening < lower limit', 'of normal (LLN).', 'E 18. Any disability acquired from trauma or another illness that, in the opinion of the', 'Investigator, could interfere with evaluation of disability due to MS.', 'E 19. Patients with known Type 1 hypersensitivity or anaphylactic reactions to the active', 'substances or any of the excipients, or intolerance of acyclovir or its therapeutic', 'equivalent.', 'Medical Conditions', 'E 20. Major systemic disease or other illness that would, in the opinion of the Investigator,', 'compromise patient safety or interfere with the interpretation of study results, eg, current', 'peptic ulcer disease, or other conditions that may predispose to hemorrhage, immune', 'cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue', 'disorders, vasculitis, inflammatory bowel disease, severe psoriasis.', \"E 21. Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion,\", \"compromise the patient's ability to understand the patient information, to give informed\", 'consent, to comply with the trial protocol, or to complete the study.', 'E 22. Major psychiatric disorder that is not adequately controlled by treatment in the opinion of', 'the Investigator.', 'E 23. Epileptic seizures that are not adequately controlled by treatment.', 'Property of the Sanofi Group - strictly confidential', 'Page 43', 'VV-CLIN-02544065 5.0']\n\n###\n\n", "completion": "END"}